Monday, September 26, 2022
    HomeHealthVC malaise, FDA confusion, & yet another Alzheimer's debate

    VC malaise, FDA confusion, & yet another Alzheimer’s debate


    Is the period of the unicorn over? What’s gotten into the FDA? And can a NASH drug ever work?

    We cowl all that and extra this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Allison DeAngelis joins us to clarify how the extended downturn for biotech shares is stoking nervousness amongst enterprise capitalists. We additionally talk about an FDA plot twist for a novel ALS therapy, a second shot for a once-promising liver drug, and the most recent within the Covid-19 pandemic.

    For extra on what we cowl, right here’s the news on biotech VCs; right here’s the story on Intercept Pharmaceuticals; right here’s more on Amylyx Pharmaceuticals; right here’s the latest on Paxlovid prescribing; right here’s where you can find episodes of Color Code; right here’s where you can subscribe to the First Opinion Podcast; and right here’s our complete coverage of the Covid-19 pandemic.


    You should definitely enroll on Apple Podcasts, Spotify, StitcherGoogle Play, or wherever you get your podcasts.

    And when you have any suggestions for us — subjects to cowl, company to ask, vocal tics to stop — you possibly can e-mail [email protected].

    Source link

    Related articles

    Stay Connected


    Latest posts